ANLN Directly Interacts with RhoA to Promote Doxorubicin Resistance in Breast Cancer Cells

Feng Wang,Zhen Xiang,Teng Huang,Min Zhang,Wei-Bing Zhou

DOI: https://doi.org/10.2147/CMAR.S261828

2020-01-01

Cancer Management and Research

Abstract:Background: Chemotherapy resistance is the leading cause of cancer treatment failure. This research was conducted to explore a potential link between actin-binding protein anillin (ANLN) and doxorubicin resistance in breast cancer. Materials and Methods: We compared ANLN expression and 50% inhibition concentra-tion (IC50) of doxorubicin in human breast cancer cells (MDA-MB-231) and human breast cancer cells with doxorubicin resistance (MDA-MB-231/ADM). Co-immunoprecipitation was used to investigate the interaction between ANLN and RhoA. The cell viability, apoptosis, gene and protein expression were estimated by MTT, flow cytometry, quantitative real-time PCR and western blot. Results: The doxorubicin resistance in MDA-MB-231/ADM cells (IC50 = 19.40 +/- 1.16 mu g/ mL) was significantly higher than that in MDA-MB-231 cells (IC50 = 1.65 +/- 0.23 mu g/mL). ANLN was up-regulated in MDA-MB-231/ADM cells compared to MDA-MB-231 cells. Furthermore, ANLN overexpression promoted cell viability and inhibited apoptosis of MDA-MB-231 cells. The gene and protein expression of multidrug resistance (MDR1) and cancer resistance protein (BCRP) were enhanced by ANLN overexpression in MDA-MB-231 cells. ANLN silencing suppressed cell viability and the expression of MDR1 and BCRP and facilitated apoptosis in MDA-MB-231/ADM cells. Moreover, ANLN promoted RhoA activation by interacting with RhoA. ANLN up-regulation enhanced cell viability and the expression of MDR1 and BCRP and decreased apoptosis of MDA-MB-231 cells. The influence conferred by ANLN overexpression was effectively abolished by C3 transferase. Conclusion: This work revealed that ANLN promoted doxorubicin resistance in breast cancer cells by activating RhoA. Thus, our study suggests a novel target for breast cancer treatment.